Acute lymphoblastic leukemia (ALL) comprises multiple entities with distinct clinico-biological features and treatment response. Among prognostic factors, cytogenetics remains one of the most discriminating parameters and is currently used to determine risk and treatment stratification. However,
No takes yet. Share an insight, caveat, or question.
Duployez et al. (2015) studied this question.
Synapse has enriched 2 closely related papers on similar clinical questions. Consider them for comparative context: